MktsMarkets

Fulcrum Therapeutics, Inc.
NASDAQ: FULCKey statistics
FULC News
Stories mentioning FULC from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 14,084 | 15,416 | 14,296 | 12,987 | 13,404 | 11,713 | 14,639 | 17,261 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 22,186 | 22,693 | 21,858 | 19,815 | 20,403 | 19,429 | 25,126 | 27,508 |
| Operating Income (Loss) | (22,186) | (22,693) | (21,858) | (19,815) | (20,403) | (19,429) | (25,126) | 52,492 |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (18,891) | (20,334) | (19,595) | (17,296) | (17,655) | (16,568) | (21,696) | 55,409 |
| Earnings Per Share (Basic) | (0.25) | (322.76) | (0.31) | (0.28) | (0.28) | (267.23) | (0.35) | 0.89 |
| Earnings Per Share (Diluted) | (0.25) | (322.76) | (0.31) | (0.28) | (0.28) | (267.23) | (0.35) | 0.87 |
| Weighted Average Shares Outstanding (Basic) | 76,215 | 63.00 | 62,597 | 62,544 | 62,479 | 62.00 | 62,409 | 62,205 |
| Weighted Average Shares Outstanding (Diluted) | 76,215 | 63.00 | 62,597 | 62,544 | 62,479 | 62.00 | 62,409 | 63,587 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About FULC
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is a stock listed on the Nasdaq Stock Market under the ticker symbol FULC. It last traded at $3.70 (Oct 30, 2026, 2:35 PM ET), down 1.9% on the day. That gives Fulcrum Therapeutics a market capitalisation of $286.9M.
Over the past 52 weeks FULC has traded between $2.83 and $15.74.
For the quarter ended Mar 31, 2026 it reported a net loss of $18.9M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$18.9M |
| Dec 31, 2025 | — | -$20.3M |
| Sep 30, 2025 | — | -$19.6M |
| Jun 30, 2025 | — | -$17.3M |
From Fulcrum Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…